CO2020000940A2 - Nanopartícula, agente de contraste para formación de imágenes de resonancia magnética que contienen el mismo, y compuesto de ligando - Google Patents

Nanopartícula, agente de contraste para formación de imágenes de resonancia magnética que contienen el mismo, y compuesto de ligando

Info

Publication number
CO2020000940A2
CO2020000940A2 CONC2020/0000940A CO2020000940A CO2020000940A2 CO 2020000940 A2 CO2020000940 A2 CO 2020000940A2 CO 2020000940 A CO2020000940 A CO 2020000940A CO 2020000940 A2 CO2020000940 A2 CO 2020000940A2
Authority
CO
Colombia
Prior art keywords
nanoparticle
magnetic resonance
contrast agent
resonance imaging
agent containing
Prior art date
Application number
CONC2020/0000940A
Other languages
English (en)
Inventor
Daigo Miyajima
Toshiaki Takeuchi
Seunghyun Sim
Takuzo Aida
Ichio Aoki
Original Assignee
Riken
National Institutes For Quantum And Radiological Science And Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, National Institutes For Quantum And Radiological Science And Tech filed Critical Riken
Publication of CO2020000940A2 publication Critical patent/CO2020000940A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona una nanopartícula novedosa, un agente de contraste para formación de imágenes de resonancia magnética que contiene el mismo, y un compuesto de ligando usado para producción de la nanopartícula. La presente invención se refiere a una nanopartícula que incluye: una partícula de metal que contiene óxido de hierro; y un ligando que se enlaza a un átomo de metal sobre una superficie de la partícula de metal y se representa por la fórmula (3): donde m en un entero de 1 hasta 4, y una línea discontinua representa un enlace coordinado con un átomo de metal sobre la superficie de la partícula de metal.
CONC2020/0000940A 2017-06-28 2020-01-27 Nanopartícula, agente de contraste para formación de imágenes de resonancia magnética que contienen el mismo, y compuesto de ligando CO2020000940A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017126755 2017-06-28
PCT/JP2018/024416 WO2019004297A1 (ja) 2017-06-28 2018-06-27 ナノ粒子、これを含む磁気共鳴イメージング用造影剤及びリガンド化合物

Publications (1)

Publication Number Publication Date
CO2020000940A2 true CO2020000940A2 (es) 2020-02-18

Family

ID=64742350

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0000940A CO2020000940A2 (es) 2017-06-28 2020-01-27 Nanopartícula, agente de contraste para formación de imágenes de resonancia magnética que contienen el mismo, y compuesto de ligando

Country Status (19)

Country Link
US (1) US11389550B2 (es)
EP (1) EP3646888A4 (es)
JP (1) JP7107532B2 (es)
KR (1) KR20200018579A (es)
CN (1) CN110799219B (es)
AU (1) AU2018292927B2 (es)
BR (1) BR112019027478A2 (es)
CA (1) CA3068215A1 (es)
CO (1) CO2020000940A2 (es)
IL (1) IL271622A (es)
JO (1) JOP20190290A1 (es)
MA (1) MA49521A (es)
MY (1) MY201491A (es)
PH (1) PH12019502882A1 (es)
RU (1) RU2767430C2 (es)
SG (1) SG11201912664WA (es)
UA (1) UA125049C2 (es)
WO (1) WO2019004297A1 (es)
ZA (1) ZA202000265B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124753A1 (en) 2018-12-27 2020-07-02 Astellas Pharma Inc. Method for producing nanoparticle having metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded
KR20210109574A (ko) * 2018-12-27 2021-09-06 아스테라스 세이야쿠 가부시키가이샤 나노 입자, 이를 함유하는 자기 공명 영상용 조영제 및 양쪽성 이온 리간드 화합물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123542A (en) 1960-10-13 1964-03-03 Electrolytic marking medium
US20100166664A1 (en) 2008-12-29 2010-07-01 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US8574549B2 (en) 2008-12-29 2013-11-05 General Electric Company Nanoparticle contrast agents for diagnostic imaging
JP6063627B2 (ja) 2008-12-29 2017-01-18 ゼネラル・エレクトリック・カンパニイ 診断イメージング用のナノ粒子造影剤
US8728529B2 (en) 2008-12-29 2014-05-20 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US8728440B2 (en) 2012-08-23 2014-05-20 General Electric Company Nanoparticulate compositions for diagnostic imaging
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US9205155B2 (en) 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
KR20130045647A (ko) * 2011-10-26 2013-05-06 한국기초과학지원연구원 양쪽성 이온으로 코팅된 자기공명영상 조영제
WO2013090601A2 (en) * 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Compact nanoparticles for biological applications
US8821838B2 (en) 2012-08-23 2014-09-02 General Electric Company Nanoparticulate compositions for diagnostic imaging
CN104740654B (zh) 2013-12-30 2017-12-29 中国科学院化学研究所 磁性纳米颗粒磁共振造影剂和增强磁性纳米颗粒弛豫率的方法
HUE046306T2 (hu) 2014-01-07 2020-02-28 Colorobbia Italiana Spa Katekollal funkcionalizált mágneses nanorészecskék, elõállításuk és alkalmazásuk
JP6471227B2 (ja) * 2014-09-15 2019-02-13 マサチューセッツ インスティテュート オブ テクノロジー 磁気共鳴画像法用途のためのナノ粒子
JP6577250B2 (ja) * 2015-06-02 2019-09-18 国立大学法人 東京大学 複合半透膜
CN106390146A (zh) 2015-08-03 2017-02-15 天津大学 聚磺酸甜菜碱两性电解质修饰的磁性纳米粒子及其制备方法和应用

Also Published As

Publication number Publication date
CN110799219A (zh) 2020-02-14
RU2019143780A (ru) 2021-06-25
RU2767430C2 (ru) 2022-03-17
CA3068215A1 (en) 2019-01-03
KR20200018579A (ko) 2020-02-19
JPWO2019004297A1 (ja) 2020-04-30
EP3646888A4 (en) 2021-04-14
US11389550B2 (en) 2022-07-19
IL271622A (en) 2020-02-27
PH12019502882A1 (en) 2020-10-26
ZA202000265B (en) 2021-07-28
MY201491A (en) 2024-02-27
US20200330617A1 (en) 2020-10-22
BR112019027478A2 (pt) 2020-07-07
MA49521A (fr) 2020-05-06
SG11201912664WA (en) 2020-01-30
CN110799219B (zh) 2023-01-06
AU2018292927A1 (en) 2020-02-06
JOP20190290A1 (ar) 2019-12-19
RU2019143780A3 (es) 2021-08-27
UA125049C2 (uk) 2021-12-29
JP7107532B2 (ja) 2022-07-27
WO2019004297A1 (ja) 2019-01-03
EP3646888A1 (en) 2020-05-06
AU2018292927B2 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
CY1124385T1 (el) Συζευγματα πυρρολοβενζοδιαζεπινων
CO2020000940A2 (es) Nanopartícula, agente de contraste para formación de imágenes de resonancia magnética que contienen el mismo, y compuesto de ligando
MX2022014611A (es) Compuestos para tomografia por emision de positrones.
SE1950904A1 (en) SOFT MAGNETIC POWDER, Fe-BASED NANOCRYSTALLINE ALLOY POWDER, MAGNETIC COMPONENT AND DUST CORE
AR100955A1 (es) Composición y método para cementación
MY180083A (en) Tetrahydropyrrolothiazine compounds
GB201114133D0 (en) Coelenterazine analogs and manufacturing method thereof
PH12015501633A1 (en) Pest-control composition and pest-control method
EP3995489A3 (en) Disulfide compounds for delivery of pharmaceutical agents
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
BR112017004214A2 (pt) processo para a preparação de pigmentos de hematita, e processo para a preparação de pigmentos vermelhos de óxido de ferro
PH12020550555A1 (en) Injectable isoxazoline pharmaceutical compositions and uses thereof
PH12019502350A1 (en) Flux composition, solder paste composition, and solder joint
BR112015015801A2 (pt) compostos de fórmula i, composição, utilização de um composto de fórmula i, método para o combate dos fungos e semente
PH12015500654A1 (en) Pest controlling composition and use thereof
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
PH12016500461A1 (en) Polyethylene glycol-containing composition
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
AU2017239848B2 (en) Novel compound and synthesis method therefor
PH12018502680A1 (en) Crystal forms of 9-aminomethyl substituted tetracycline compound and preparation method thereof
ES2649168T3 (es) Método de fabricación de un compuesto de piridazinona
MX2018013410A (es) Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.
MX2021005999A (es) Composiciones de quelatos metalicos o complejos metalicos que comprenden nanoparticulas minimas.
MX2017003290A (es) Proceso para la preparacion de derivados de trifenilbuteno.
MY177032A (en) Aqueous composition